Literature DB >> 23329816

Neuromotor control in chronic obstructive pulmonary disease.

Carlos B Mantilla1, Gary C Sieck.   

Abstract

Neuromotor control of skeletal muscles, including respiratory muscles, is ultimately dependent on the structure and function of the motor units (motoneurons and the muscle fibers they innervate) comprising the muscle. In most muscles, considerable diversity of contractile and fatigue properties exists across motor units, allowing a range of motor behaviors. In diseases such as chronic obstructive pulmonary disease (COPD), there may be disproportional primary (disease related) or secondary effects (related to treatment or other concomitant factors) on the size and contractility of specific muscle fiber types that would influence the relative contribution of different motor units. For example, with COPD there is a disproportionate atrophy of type IIx and/or IIb fibers that comprise more fatigable motor units. Thus fatigue resistance may appear to improve, while overall motor performance (e.g., 6-min walk test) and endurance (e.g., reduced aerobic exercise capacity) are diminished. There are many coexisting factors that might also influence motor performance. For example, in COPD patients, there may be concomitant hypoxia and/or hypercapnia, physical inactivity and unloading of muscles, and corticosteroid treatment, all of which may disproportionately affect specific muscle fiber types, thereby influencing neuromotor control. Future studies should address how plasticity in motor units can be harnessed to mitigate the functional impact of COPD-induced changes.

Entities:  

Keywords:  diaphragm muscle; fiber type; motor control; motor unit; respiratory muscles

Mesh:

Year:  2013        PMID: 23329816     DOI: 10.1152/japplphysiol.01212.2012

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  9 in total

Review 1.  Mechanical properties of respiratory muscles.

Authors:  Gary C Sieck; Leonardo F Ferreira; Michael B Reid; Carlos B Mantilla
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

Review 2.  Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  Esther Barreiro; Joaquim Gea
Journal:  Chron Respir Dis       Date:  2016-04-06       Impact factor: 2.444

Review 3.  Spinal cord injury and diaphragm neuromotor control.

Authors:  Matthew J Fogarty; Gary C Sieck
Journal:  Expert Rev Respir Med       Date:  2020-02-25       Impact factor: 3.772

4.  Impact of sarcopenia on diaphragm muscle fatigue.

Authors:  Matthew J Fogarty; Carlos B Mantilla; Gary C Sieck
Journal:  Exp Physiol       Date:  2019-04-22       Impact factor: 2.969

5.  Respiratory motor training and neuromuscular plasticity in patients with chronic obstructive pulmonary disease: A pilot study.

Authors:  Alexander V Ovechkin; Dimitry G Sayenko; Elena N Ovechkina; Sevda C Aslan; Teresa Pitts; Rodney J Folz
Journal:  Respir Physiol Neurobiol       Date:  2016-04-29       Impact factor: 1.931

Review 6.  Impact of diaphragm muscle fiber atrophy on neuromotor control.

Authors:  Carlos B Mantilla; Gary C Sieck
Journal:  Respir Physiol Neurobiol       Date:  2013-07-02       Impact factor: 1.931

Review 7.  Common mechanisms of compensatory respiratory plasticity in spinal neurological disorders.

Authors:  Rebecca A Johnson; Gordon S Mitchell
Journal:  Respir Physiol Neurobiol       Date:  2013-05-28       Impact factor: 1.931

8.  Muscle-specific deletion of the vitamin D receptor in mice is associated with diaphragm muscle weakness.

Authors:  Matthew J Fogarty; Louis L Losbanos; Theodore A Craig; Carmen J Reynolds; Alyssa D Brown; Rajiv Kumar; Gary C Sieck
Journal:  J Appl Physiol (1985)       Date:  2021-05-20

9.  Epigenetic mechanisms in respiratory muscle dysfunction of patients with chronic obstructive pulmonary disease.

Authors:  Ester Puig-Vilanova; Rafael Aguiló; Alberto Rodríguez-Fuster; Juana Martínez-Llorens; Joaquim Gea; Esther Barreiro
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.